MannKind

Yahoo Finance • 21 days ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Five presentations affirm positive outcomes utilizing inhaled insulinAn sNDA filing for Afrezza in pediatric population anticipated in 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- MannKind Corpora... Full story

Yahoo Finance • 6 months ago

MannKind Corporation (MNKD): Short Seller Sentiment is Bearish

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers.In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against the other 52-week high stocks. The s... Full story

Yahoo Finance • last year

MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million

MannKind Sagard Healthcare purchased a 1% royalty in Tyvaso DPI® net sales Purchase price of $150 million; additional potential milestone payment of up to $50 million WESTLAKE VILLAGE, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- MannKind... Full story

Yahoo Finance • last year

Insider Sell: CEO Michael Castagna Offloads 200,482 Shares of MannKind Corp (MNKD)

In a significant move within the pharmaceutical industry, CEO Michael Castagna has parted with a substantial number of shares in MannKind Corp (NASDAQ:MNKD). On December 15, 2023, the insider executed a sale of 200,482 shares, a transactio... Full story

Yahoo Finance • last year

MannKind Corporation Reports 2023 Third Quarter Financial Results

Conference Call to Begin Today at 5:00 p.m. (ET) 3Q 2023 Total revenues of $51M; +56% vs. 3Q 20223Q YTD 2023 Total revenues of $140M; +121% vs. 3Q YTD 20223Q 2023 Net income of $2M; Non-GAAP net income of $4M3Q 2023 Tyvaso DPI royalties o... Full story

Yahoo Finance • last year

MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes

Rapidly enrolled 141 patients in less than four monthsLarge study will compare A1c from baseline to 17 weeks for adults when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Initial... Full story

Yahoo Finance • last year

MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent

Patent covers compositions of clofazimine, and methods for treating lung infectionsDevelopment of MNKD-101 (inhaled clofazimine) continues for the potential treatment of nontuberculous mycobacterial (NTM) lung disease DANBURY, Conn., Oct.... Full story

Yahoo Finance • 2 years ago

MannKind Corporation Announces Participation at Upcoming Conferences

WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with... Full story

Yahoo Finance • 2 years ago

12 Best High Risk Penny Stocks to Buy Now

In this article, we will take a look at the 12 best high risk penny stocks to buy now. To see more such companies, go directly to 5 Best High Risk Penny Stocks to Buy Now. Investors are jubilant over Nvidia crushing analyst estimates in i... Full story

Yahoo Finance • 2 years ago

MannKind Launches Inhale-3 Study to Address the Most Important Unmet Need Today in Adults Living With Type 1 Diabetes (T1D)

Large trial in adults comparing A1c and mealtime control when switching from injectable insulin or pumps to inhaled insulin (Afrezza® (insulin human) Inhalation Powder)Time-in-range during waking hours remains a challenge despite advances... Full story

Yahoo Finance • 2 years ago

Governor Ned Lamont to Tour MannKind June 12 as It Reaches a Manufacturing Milestone

DANBURY, Conn., June 11, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will host Connecticut Governor Ned Lamont for a tour of its headquarters on Monday, June 12. The visit coincides with MannKind reaching a manufacturing... Full story

Yahoo Finance • 2 years ago

MannKind Corporation to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with e... Full story

Yahoo Finance • 2 years ago

CORRECTION -- MannKind Corporation Reports 2023 First Quarter Financial Results

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by MannKind Corporation (Nasdaq: MKND), please note in the second table, titled "CONDENSED CONSOLIDAT... Full story

Yahoo Finance • 2 years ago

Mannkind Corporation Reports 2023 First Quarter Financial Results

1Q 2023 Total Revenues of $41 million; +239% vs. 1Q 2022 1Q 2023 Revenues associated with Tyvaso DPI of $23 million 1Q 2023 Loss from operations decreased 72% vs. 1Q 2022 to $6 million $167 million of Cash, Cash Equivalents and Investments... Full story

Yahoo Finance • 2 years ago

MannKind Corporation to Hold 2023 First Quarter Financial Results Conference Call on May 9, 2023

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2023 first quarter financial results and its management will host a conference call to discuss the financi... Full story

Yahoo Finance • 2 years ago

Lauren Sabella Joins Mannkind as Executive Vice President, Chief Operating Officer

DANBURY, Conn., March 27, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung di... Full story

Yahoo Finance • 2 years ago

MannKind Corporation to Participate in Oppenheimer 33rd Annual Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 07, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with... Full story

Yahoo Finance • 2 years ago

MannKind Corporation Reports 2022 Fourth Quarter and Full Year Financial Results

2022 Total Revenues of $100 million; +32% vs. 20212022 Royalties from Tyvaso DPI of $16 million; 4Q 2022 of $9 million4Q 2022 Commercial Products Net Revenue of $17 million;+54% vs. 4Q 2021$173 million of Cash and Cash Equivalents and Inve... Full story

Yahoo Finance • 2 years ago

MannKind to Give Oral Presentation on Meal Challenge Results From the Afrezza® With Basal Combination (ABC Study) at 16th Annual ATTD Conference

Inhaled Technosphere® Insulin (TI) lowered peak glucose levels 30 minutes faster than injectable rapid-acting insulin delivered through an AID insulin pump and significantly lowered post-prandial glucose (PPG) from 45-120 minutes after a c... Full story

Yahoo Finance • 2 years ago

MannKind Corporation to Hold 2022 Fourth Quarter and Full Year Financial Results Conference Call on February 23, 2023

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) will release its 2022 fourth quarter and full year financial results and its management will host a conference call to dis... Full story